Publications by authors named "Dimitar T Kostadinov"
Biomarker research in COPD is becoming the most rapidly progressing sphere in respiratory medicine. Although "omics" generate a huge amount of biomarkers, fibrinogen is the only one validated by the European Medicines Agency. Thousands of studies analyzing different biological samples from the respiratory tract, collected in different ways, using various kits and techniques are generating more and more data, rendering biomarkers very confusing rather than having practical value.
View Article and Find Full Text PDFBackground: Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement mutation are found to be 3-13%.
Aim: To evaluate the prevalence of ALK mutations in EGFR-negative NSCLC patients in Bulgaria.
Materials And Methods: One hundred and thirty-two patients with EGFR-negative NSCLC were examined for ALK mutation analysis between January and June 2016.
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) is a manageable disease with various health impacts beyond the lungs, while hepatitis C virus (HCV) infection also has multiple non-liver-related health issues.
- There is a notable overlap between the two conditions, as patients with COPD have higher rates of HCV, and those infected with HCV, particularly older individuals, tend to experience quicker deterioration of their lung function.
- The article reviews research on the coexistence of COPD and HCV, examining their prevalence, underlying mechanisms, and the health consequences of having both conditions simultaneously.
Introduction: One-year mortality in COPD patients is reported to be between 4% and 43%, depending on the group examined.
Aim: To examine the one-year mortality in COPD patients after severe exacerbation and the correlation between mortality and patients' characteristics and comorbidities.
Methods: A total of 152 COPD patients hospitalized for severe exacerbation were assessed for vitamin D status, diabetes mellitus (DM), arterial hypertension (AH), and metabolic syndrome (MS).
Introduction: Diabetes mellitus (DM) is estimated to affect 2-37% of COPD patients, results varying widely between studies. DM may also correlate with quality of life and lung function.
Aim: To examine correlations between DM and quality of life and lung function in COPD patients admitted to hospital with exacerbation of COPD.